Poseida Therapeutics, Inc.

45 articles with Poseida Therapeutics, Inc.

• Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

  4/8/2021

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:

• Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board

  3/23/2021

   Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of distinguished scientist Carl June, M.D., who will serve on Poseida's Scientific Advisory Board (SAB).

• Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

  3/11/2021

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020.

• Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day

  2/24/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day

• Poseida Therapeutics to Host Virtual R&D Day on February 24, 2021

  2/10/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 2:00 pm ET / 7:00 - 11:00 am PT on Wednesday, February 24, 2021.

• Poseida Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

  2/4/2021

  Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag , M.D., Ph.D., Poseida Therapeutics' Chief Executive Officer, will participate in a fireside chat on February 12, 2021

• Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event

  1/4/2021

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag , M.D., Ph.D., Poseida Therapeutics' Chief Executive Officer, will participate in a pre-reco

• Poseida Therapeutics Added to NASDAQ Biotechnology Index

  12/18/2020

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI)

• Poseida Therapeutics Appoints Luke Corning to Board of Directors

  12/17/2020

  Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Luke Corning, Portfolio Manager and Head of Credit at Pentwater Capital Management, to its Board of Directors. 

• 

  ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope

  12/7/2020

  The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.

• Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

  12/5/2020

  Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile

• Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020

  11/12/2020

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced an operational update and financial results for the quarter ended September 30, 2020.

• Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

  11/2/2020

   Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the U.S. Food and Drug Administration (FDA) has lifted a clinical hold on the Company's Phase 1 study of P-PSMA-101

• Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index

  9/18/2020

  Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced its addition as a member of the US small-cap Russell 2000® Index,

• Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020

  9/16/2020

  Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today will present data related to its proprietary manufacturing process designed to optimize its CAR-T product candidates.

• 

  Clinical Catch-Up: August 17-21

  8/24/2020

  It was a relatively quiet week for clinical trial news. Here’s a look.

• Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020

  8/20/2020

   Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced an operational update and financial results for the quarter ended June 30, 2020 .

• 

  FDA Halts Poseida’s CAR-T Trial for Prostate Cancer Following Patient Death

  8/18/2020

  Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.

• Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel

  7/16/2020

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced biotech veteran Harry J. Leonhardt, Esq. has joined the company as General Counsel and Chief Com

• Poseida Therapeutics Announces Pricing of Initial Public Offering

  7/9/2020

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the pricing of its initial public offering of 14,000,000 shares of its common stock at a price to the public of $16.00 per share